Republished: Real-time MRI guidance for intra-arterial drug delivery in a patient with a brain tumor: technical note.
Michal ZawadzkiJerzy WaleckiBoguslaw KostkiewiczKacper KostyraMonica Smith PearlMeiyappan SolaiyappanPiotr WalczakMiroslaw JanowskiPublished in: Journal of neurointerventional surgery (2019)
Patients suffering from malignant brain tumors are burdened with a grim prognosis. The blood brain barrier is considered a primary obstacle in therapeutic drug delivery to the brain. Intra-arterial (IA) delivery of therapeutic agents following osmotic BBB opening has been attempted for years, but high variability has limited its widespread implementation. It has been recently shown in animal studies that MRI is superior to X-ray for guiding IA infusions, as it allows direct visualization of the brain parenchyma perfused and facilitates predictable drug targeting. Moreover, PET imaging has revealed that IA, not intravenous, delivery of bevacizumab results in brain accumulation, providing strong rationale for utilizing the IA route. Here, we present our experience in a patient with recurrent butterfly glioblastoma enrolled in first-in-man MRI-guided neurointervention for targeted IA drug delivery.
Keyphrases
- drug delivery
- cancer therapy
- pet imaging
- contrast enhanced
- resting state
- magnetic resonance imaging
- white matter
- case report
- functional connectivity
- diffusion weighted imaging
- end stage renal disease
- newly diagnosed
- primary care
- healthcare
- ejection fraction
- drug release
- high resolution
- clinical trial
- emergency department
- blood brain barrier
- multiple sclerosis
- patient reported outcomes
- mass spectrometry
- single cell
- adverse drug
- case control